The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses the results from a study looking at immune-related adverse events (irAEs) with immunotherapy drugs for the treatment of genitourinary cancers. The study that Dr Dorff talks about was presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 conference in San Francisco last week.

See Dr Dorff’s interview on Practice Update here